Human tumours frequently harbour activating mutations in PIK3CA (or p110α, the catalytic subunit of PI3K) or inactivating mutations in PTEN (negative regulator of the PI3K-AKT pathway), leading to over-stimulation of PI3K-AKT pathway activity [8]. The gene discussed is AKT1; the disease is neoplasm.